Xeris reveals topline data from ongoing Phase 2 study of RTU glucagon
Category: #healthcare  By Mateen Dalal  Date: 2019-12-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Xeris reveals topline data from ongoing Phase 2 study of RTU glucagon

Xeris Pharmaceuticals, Inc., a specialty biotechnology firm that commercializes and develops ready-to-use (RTU) infusible and injectable drug formulations, has recently revealed topline results from its in-clinic stage Phase 2 trial of developmental RTU glucagon in patients that endure postprandial hypoglycemic episodes after bariatric surgery.

As per reports, the Phase 2 randomized, prospective, double-blind, placebo-controlled trial involved an in-clinic stage which was followed by a 12-week outpatient phase. Reportedly, the findings revealed that nearly every patient faced postprandial hypoglycemia within 90-120 minutes of their meals.

Amidst this successful meal challenge, it was also observed that patients were able to self-administer a small dosage of study drug, as prescribed while experiencing a shortage of blood glucose.

According to Paul R. Edick, Chairman and CEO, Xeris, the company is pleased with the results of the in-clinic phase of its PBH trial. The initial part of this trial marked as a significant step towards demonstrating the efficacy of stable, liquid, RTU glucagon in circumstances beyond rescue for acute hypoglycemia. It also showcased effectiveness and safety in events that demand self-administration by the patient.

He added that Xeris believes the remaining half of the trial, which isn’t controlled by the in-clinic environment, would positively proceed in demonstrating the mini dosing of RTU glucagon’s safety profile. This data would be accessible in the Q1-Q2 of 2020.

Prior to this news, Xeris Pharmaceuticals came into limelight when it revealed choosing Mark Thierer to be a part of its Board of Directors. This addition takes the board to seven members. Mr. Thierer would also become a participant of the Audit Committee.

Speaking of which, Mr. Edick commented that the company welcomes Mark Thierer and his immense experience & insights of this industry. As Xeris continues to grow into a commercial company, the firm is looking forward to partnering with Mark to design its strategic plans and further their vision.
 

Source Credit: https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-announces-positive-topline-results-clinic

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

LSU Health to test nitric oxide for better COVID-19 patient outcomes
LSU Health to test nitric oxide for better COVID-19 patient outcomes
By Mateen Dalal

LSU Health, a renowned public university focused on health sciences, has now reportedly become one o...

CSC buys TCS, expands alternative investment fund capabilities in Europe
CSC buys TCS, expands alternative investment fund capabilities in Europe
By Mateen Dalal

CSC, a leading firm providing legal, tax, as well as digital and business services across the world,...

Evotec partners with panCELLa to enhance cell therapy plaform
Evotec partners with panCELLa to enhance cell therapy plaform
By Mateen Dalal

Evotec gains access to panCELLa’s iPS cell lines known as- iACT Stealth Cells™ The c...